

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Health Technology Appraisal**

# Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6148

## **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
Company	
Company	General
Roche (atezolizumab)	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
Patient/carer groups	Allied Health Professionals Federation
<ul> <li>Addenbrookes Liver Transplant</li> </ul>	
Association	Board of Community Health Councils in Wales
Black Health Agency for Equality	British National Formulary
British Liver Trust	Care Quality Commission
Cancer Black Care	Department of Health, Social Services
Cancer Equality	and Public Safety for Northern Ireland
• Cancer 52	Healthcare Improvement Scotland
GUTS UK	Medicines and Healthcare products
Helen Rollason Cancer Charity	Regulatory Agency
Hepatitis C Trust	National Association of Primary Care
Independent Cancer Patients' Voice	National Pharmacy Association
Liver4Life	NHS Confederation
Macmillan Cancer Support	Scottish Medicines Consortium
Maggie's Centres	Scottish Society of Gastroenterology
Marie Curie	Welsh Government
Pelican Cancer Foundation	Welsh Health Specialised Services
South Asian Health Foundation	Committee
Specialised Healthcare Alliance	
Tenovus Cancer Care	Possible comparator companies
Tonovao Ganoor Garo	None
Healthcare professional groups	
Association of Anaesthetists of Great	Relevant research groups
Britain & Ireland	Cochrane Hepato-biliary Group
Association of Cancer Physicians	Cochrane Infectious Diseases Group
Association of Surgeons of Great	Cochrane UK
Britain & Ireland	Foundation for Liver Research
British Association of the Study of the	Genomics England
Liver	Institute of Cancer Research
British Geriatrics Society	MRC Clinical Trials Unit
British Institute of Radiologists	National Institute for Health Research
British Oncology Pharmacy	
Association	Associated Public Health group

Provisional stakeholder list for the evaluation of atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6148 Issue date: January 2024



Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Psychosocial Oncology Society</li> <li>British Society of Gastroenterology</li> <li>Cancer Research UK</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiologists</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul>	<ul> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
<ul><li>Others</li><li>Department of Health and Social Care</li><li>NHS England</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Provisional stakeholder list for the evaluation of atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6148 Issue date: January 2024





Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.